Investor science conference call American Society of Hematology. 9 December 2013, New Orleans, USA

Size: px
Start display at page:

Download "Investor science conference call American Society of Hematology. 9 December 2013, New Orleans, USA"

Transcription

1 Investor science conference call American Society of Hematology 9 December 2013, New Orleans, USA

2 Forward-looking statements This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forwardlooking statements contained in this presentation, among others: pricing and product initiatives of competitors legislative and regulatory developments and economic conditions delay or inability in obtaining regulatory approvals of bringing products to market uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products increased government pricing pressures interruptions in production loss of or inability to obtain adequate protection for intellectual property rights litigation loss of key executives or other employees adverse publicity and news coverage fluctuations in currency exchange rates and general financial market conditions Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website All mentioned trademarks are legally protected. 2

3 Agenda for the conference call Expected duration ~75 minutes ~5 minutes ~20 minutes ~10 minutes ~10 minutes ~30 minutes Introduction Dr. Karl Mahler, Head of Investor Relations Gazyva(obinutuzumab): The CLL11 study Dr. Valentin Goede, Principal Investigator University Hospital of Cologne, Germany Gazyva: Newest Roche oncology product Dr. Thomas Buechele, Lifecycle Leader Hematology franchise update Rick Fair, Franchise Head Q&A 3

4 2011 to present: Strong pipeline progression 29 successful late-stage trials Zelboraf BRIM 3 Erivedge ERIVANCE Onartuzumab NSCLC Herceptin SC HANNAH Lucentis HARBOR Avastin mcrc TML Dalcetrapib dal-outcomes Herceptin HERA2 Avastin Cervical Aleglitazar AleCardio Avastin OCEANS Actemra ACT-Ray Perjeta CLEOPATRA Actemra BUILDER I/II Actemra CHERISH MabThera/ Rituxan SC SABRINA Actemra BREVACTA Avastin AVAGLIO Gazyva CLL Tarceva EURTAC Lucentis RISE Kadcyla Phase II Avastin+ pemetrexed AVAPERL Avastin+ Herceptin AVEREL Actemra ADACTA Kadcyla EMILIA Xolair ASTERIA Actemra SUMMACTA Onartuzumab T-N BC Kadcyla TH3RESA Lucentis RIDE Lebrikizumab MILLY Gazyva GAUSS Avastin AURELIA Avastin BEATRICE Actemra FUNCTION Xolair GLACIAL Positive trials New molecular entity 4

5 Never settle for great 1.0 HER2 franchise Replace & Extend Extend Perjeta MEDICAL VALUE Herceptin + chemo Lapatinib + chemo Replace Kadcyla Herceptin + chemo Perjeta Kadcyla Illustrative EMILIA / MARIANNE study CLEOPATRA study MARIANNE study 5

6 Never settle for great 2.0 Hematology franchise Replace & Extend Replace Extend BCL2 BCL2 ADC CD22 ADC CD79b MEDICAL VALUE MabThera/ Rituxan combos Gazyva combo(s) Chemo MabThera/ Rituxan ADC CD22 ADC CD79b Other molecules Gazyva Other molecules Illustrative CLL11 study, etc. E.g. ROMULUS study Our vision 6

7 Gazyva(obinutuzumab): The CLL11 study Dr. Valentin Goede, Principal Investigator University Hospital of Cologne, Germany

8 Head-to-Head Comparison of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb in Patients With Chronic Lymphocytic Leukemia (CLL) and Co-existing Medical Conditions (Comorbidities): Final Stage 2 Results of the CLL11 Trial Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, De la Serna J, Dilhuydy MS, Opat S, Owen C, Samoylova O, Kreuzer KA, Langerak AW, Ritgen M, Stilgenbauer S, Döhner H, Asikanius E, Humphrey K, Wenger M, Hallek M 8

9 GA101: A type II, glycoengineered CD20 antibody CD20 peptide Heavy chain Type II CD20 antibody Light chain Glycoengineered Fc-region Niederfellner et al., Blood, 2011; Ferrara et al., PNAS,

10 GA101: Mechanisms of action Increased Direct Cell Death Type II vs Type I antibody Enhanced ADCC Glycoengineering for increased affinity to FcγRIIIa Effector cell B cell Lower CDC Type II vs Type I antibody GA101 CD20 Complement FcγRIIIa ADCC, 10 antibody-dependent cell-mediated cytotoxicity; CDC, complement-dependent cytotoxicity Mössner et al. Blood 2010;115:

11 Study goals Ø To establish chemoimmunotherapy in older patients with CLL and comorbidities Ø To compare GA101 head-to-head with rituximab (as the standard of care) 11

12 Study design Previously untreated CLL Total CIRS score >6 and/or creatinine clearance <70 ml/min N=780 (planned) R A N D O M I Z E 2:1:2 GA101 + chlorambucil x 6 cycles Chlorambucil x 6 cycles (control arm) Rituximab + chlorambucil x 6 cycles 12 GA101: 1000 mg days 1, 8, and 15 cycle 1; day 1 cycles 2 6, every 28 days Rituximab: 375 mg/m 2 day 1 cycle 1, 500 mg/m 2 day 1 cycles 2 6, every 28 days Chlorambucil: 0.5 mg/kg day 1 and day 15 cycle 1 6, every 28 days Patients with progressive disease in the Clb arm were allowed to cross over to G-Clb 12

13 Study design 590 patients Previously untreated CLL Total CIRS score >6 and/or creatinine clearance <70 ml/min N=780 (planned) R A N D O M I Z E 2:1:2 GA101 + chlorambucil x 6 cycles Chlorambucil x 6 cycles (control arm) Rituximab + chlorambucil x 6 cycles G-Clb vs. Clb Primary analysis data cut-off: 07/

14 Study design 590 patients Previously untreated CLL Total CIRS score >6 and/or creatinine clearance <70 ml/min N=780 (planned) R A N D O M I Z E 2:1:2 GA101 + chlorambucil x 6 cycles Chlorambucil x 6 cycles (control arm) Rituximab + chlorambucil x 6 cycles G-Clb vs. Clb Primary analysis data cut-off: 07/2012 R-Clb vs. Clb Primary analysis data cut-off: 08/

15 Study design 590 patients Additional 190 patients Previously untreated CLL Total CIRS score >6 and/or creatinine clearance <70 ml/min N=780 (planned) R A N D O M I Z E 2:1:2 GA101 + chlorambucil x 6 cycles Chlorambucil x 6 cycles (control arm) Rituximab + chlorambucil x 6 cycles G-Clb vs. R-Clb Primary analysis data cut-off: 05/

16 Study assumptions Hazard ratio (HR): G-Clb vs. R-Clb 0.74 G-Clb vs. Clb 0.44 R-Clb vs. Clb 0.60 Median progression-free survival (PFS): G-Clb 27 months R-Clb 20 months Clb 12 months 16

17 Patient disposition G-Clb R-Clb Randomized Received treatment Median observation time 18.7 months Efficacy analysis n = 663 (ITT) Safety analysis n =

18 Baseline patient characteristics G-Clb (n=333) % R-Clb (n=330) % Male Median age, years (range) 74 (39 89) 73 (40 90) Aged 65 years Aged 75 years Median ECOG PS (range) 1 (0-3) 1 (0-3) Median CIRS score CIRS score > Median CrCl CrCl <70 ml/min CrCl <50 ml/min ECOG PS, Eastern Cooperative Oncology Group performance status; CIRS, cumulative illness rating scale; CrCl, creatinine clearance 18

19 Baseline disease characteristics Binet stage G-Clb (n=333) % R-Clb (n=330) % A B C FISH cytogenetics 17p q q Other 7 8 Normal IGHV status Unmutated FISH, fluorescence in situ hybridization; IGHV, immunoglobulin heavy chain variable region 19

20 Adverse events of interest G-Clb (n=336) a % R-Clb (n=321) a % Any AE grade 3 b Infusion-related reaction 20 4 Neutropenia Anemia 4 4 Thrombocytopenia 10 3 Infection Pneumonia 4 5 a Safety population for G-Clb includes 5 patients randomized to R-Clb who received one infusion of GA101 in error b Incidence rate of 3% in any treatment arm 20

21 End-of-treatment response G-Clb (n=333) % R-Clb (n=329) a % Response rate ORR p < CR b 21 7 PR c SD 5 15 PD 4 11 Not evaluable d 13 9 a Assessment not reached by data cut-off in 1 patient in R-Clb arm; as assessed by iwcll criteria 3 months after end of treatment b Confirmed by imaging and bone marrow, and includes incomplete CR c Includes nodular PR d Due to missing data or withdrawal from study treatment prior to response assessment ORR, overall response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease 21

22 Minimal residual disease (MRD) As measured by central laboratory assessment (ASO-RQ-PCR) at 3 months after end of treatment; bone marrow samples were usually only taken from patients thought to be in CR 22

23 Progression-free survival (Head-to-Head) Progression-free survival No. at risk G-Clb: R-Clb: Time (months) Median observation time: G-Clb, 18.8 months; R-Clb, 18.6 months Type 1 error controlled through closed test procedure; P value of the global test was < Independent Review Committee-assessed progression-free survival (PFS) was consistent with investigator-assessed PFS 23

24 PFS subgroup analysis (Head-to-Head) 24

25 Treatment comparisons R A N D O M I Z E 2:1:2 GA101 + chlorambucil x 6 cycles Chlorambucil x 6 cycles (control arm) Rituximab + chlorambucil x 6 cycles G-Clb vs. R-Clb 25 R A N D O M I Z E 2:1:2 GA101 + chlorambucil x 6 cycles Chlorambucil x 6 cycles (control arm) Rituximab + chlorambucil x 6 cycles G-Clb vs. Clb R-Clb vs. Clb 25

26 Progression-free survival (Rituximab) Progression-free survival No. at risk R-Clb: Clb: Time (months) Median observation time: R-Clb, 23.2 months; Clb, 20.4 months Type 1 error controlled through closed test procedure; P value of the global test was < Independent Review Committee-assessed PFS was consistent with investigator-assessed PFS 26

27 Progression-free survival (GA101) Progression-free survival No. at risk G-Clb: Clb: Time (months) Median observation time: G-Clb, 23.2 months; Clb, 20.4 months Type 1 error controlled through closed test procedure; P value of the global test was < Independent Review Committee-assessed PFS was consistent with investigator-assessed PFS 27

28 Overall survival (Rituximab) Overall survival No. at risk R-Clb: Clb: Time (months) Median observation time: R-Clb, 23.2 months; Clb, 20.4 months No multiplicity adjustment was done for secondary endpoints Total number of deaths: R-Clb, 34 (15%); Clb, 24 (20%) 28

29 Overall survival (GA101) Overall survival No. at risk G-Clb: Clb: Time (months) Median observation time: G-Clb, 23.2 months; Clb, 20.4 months No multiplicity adjustment was done for secondary endpoints Total number of deaths: G-Clb, 22 (9%); Clb, 24 (20%) 29

30 Overall survival (Head-to-Head) Overall survival No. at risk G-Clb: R-Clb: Time (months) Median observation time: G-Clb, 18.8 months; R-Clb, 18.6 months No multiplicity adjustment was done for secondary endpoints Total number of deaths: G-Clb, 28 (8%); R-Clb, 41 (12%) 30

31 Summary G-Clb as first-line treatment of CLL patients with comorbidities: Acceptable safety profile Prolongation of overall survival Superior to R-Clb (PFS, CR, MRD) 31

32 Conclusions Ø Type II character and glycoengineering of GA101 improve anti-cd20 therapy in CLL Ø Induction of deep remissions changes the course of CLL even in elderly patients (as seen with GA101) 32

33 Gazyva: Newest Roche oncology product Dr. omas Buechele, Lifecycle Leader Roche Pharma, Global Product Strategy

34 Gazyva: Additional data at ASH 2013 Key data highlights in CLL & a/inhl CLL Presentation anhl Poster inhl Poster Safety and efficacy of Gazyva (GA101) with fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of patients with chronic lymphocytic leukemia (CLL): results from the phase 1b GALTON trial (GAO4779g) Safety and efficacy of Gazyva (GA101) plus CHOP chemotherapy in first-line advanced diffuse large B-cell lymphoma: results from the phase 2 GATHER study (GAO4915g) Gazyva (GA101) plus CHOP or FC in relapsed/ refractory follicular lymphoma: final data from the maintenance phase of the phase 1b GAUDI study (BO21000) Key Insights From GALTON Gazyva plus B or FC chemotherapy can be administered safely to 1 st line CLL patients; data show clinical activity in 1 st line CLL warranting further clinical study FC=fludarabine, cyclophosphamide, B=bendamustine, CHOP=cyclophosphamide, doxorubicin, vincristine, prednisone 34

35 Gazyva: Additional data at ASH 2013 Key data highlights in CLL & a/inhl CLL Presentation anhl Poster inhl Poster Safety and efficacy of Gazyva (GA101) with fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of patients with chronic lymphocytic leukemia (CLL): results from the phase 1b GALTON trial (GAO4779g) Safety and efficacy of Gazyva (GA101) plus CHOP chemotherapy in first-line advanced diffuse large B-cell lymphoma: results from the phase 2 GATHER study (GAO4915g) Gazyva (GA101) plus CHOP or FC in relapsed/ refractory follicular lymphoma: final data from the maintenance phase of the phase 1b GAUDI study (BO21000) Phase III GREEN study (n=800) will further explore and test Gazyva + various chemotherapies in CLL FC=fludarabine, cyclophosphamide, B=bendamustine, CHOP=cyclophosphamide, doxorubicin, vincristine, prednisone 35

36 Gazyva: Additional data at ASH 2013 Key data highlights in CLL & a/inhl CLL Presentation anhl Poster inhl Poster Safety and efficacy of Gazyva (GA101) with fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of patients with chronic lymphocytic leukemia (CLL): results from the phase 1b GALTON trial (GAO4779g) Safety and efficacy of Gazyva (GA101) plus CHOP chemotherapy in first-line advanced diffuse large B-cell lymphoma: results from the phase 2 GATHER study (GAO4915g) Gazyva (GA101) plus CHOP or FC in relapsed/ refractory follicular lymphoma: final data from the maintenance phase of the phase 1b GAUDI study (BO21000) Key Insights From GATHER G-CHOP was safely administered to patients with newly diagnosed DLBCL; data provide further rationale for ongoing phase 3 GOYA study FC=fludarabine, cyclophosphamide, B=bendamustine, CHOP=cyclophosphamide, doxorubicin, vincristine, prednisone 36

37 Gazyva: Additional data at ASH 2013 Key data highlights in CLL & a/inhl CLL Presentation anhl Poster inhl Poster Safety and efficacy of Gazyva (GA101) with fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of patients with chronic lymphocytic leukemia (CLL): results from the phase 1b GALTON trial (GAO4779g) Safety and efficacy of Gazyva (GA101) plus CHOP chemotherapy in first-line advanced diffuse large B-cell lymphoma: results from the phase 2 GATHER study (GAO4915g) Gazyva (GA101) plus CHOP or FC in relapsed/ refractory follicular lymphoma: final data from the maintenance phase of the phase 1b GAUDI study (BO21000) Key Key Insights Insights From From GATHER GAUDI G-CHOP was safely administered Gazyva maintenance monotherapy to patients with newly diagnosed is well tolerated and confers DLBCL; data provide further clinical benefit after induction with rationale for ongoing phase 3 Gazyva plus chemotherapy GOYA study FC=fludarabine, cyclophosphamide, B=bendamustine, CHOP=cyclophosphamide, doxorubicin, vincristine, prednisone 37

38 Introducing Gazyva Now FDA approved US: Approved 1 November 2013 Gazyva, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) Course of treatment 8,000 mgs in nine infusions over six months EU, RoW: Approval expected in 2014 Gazyva: US trade name as approved by the FDA 38

39 Gazyva in CLL: Advancing the standard of care in patients with co-morbidities MabThera/Rituxan oncology sales by indications (2012 oncology sales ~CHF 5.6bn) 1st line CLL patient populations Indolent NHL ~50% Aggressive NHL ~30% CLL ~20% ~45% ~55% CLL11 study patient population Treatment options today: 3-25% treated with chlorambucil (varies by country) ~30% other 1 MabThera/Rituxan+fludarabine/cyclophosphamide or MabThera/Rituxan+bendamustine combinations Intolerant to intensive chemotherapy 1 Other: MabThera/Rituxan monotherapy, bendamustine monotherapy or combinations of MabThera-Rituxan and either low dose fludarabine+cyclophosphamide, low dose fludarabine or bendamustine 39

40 The Gazyva GATEWAY program Four pivotal phase III trials, three of them H2H versus MabThera/Rituxan, recruiting in total ~4000 patients. All the studies have recruited/are recruiting ahead of schedule H2H CLL 1 st line co-morbid CLL11 n = 781 G-Clb vs R-Clb vs Clb H2H DLBCL 1 st line GOYA n = 1400 G-CHOP vs R-CHOP inhl Rituxan-refractory GADOLIN n = 410 G-B G-maintenance vs B H2H inhl 1 st line w/maintenance GALLIUM n = 1400 G-chemo G-maintenance vs R-chemo R-maintenance G=Gazyva, R=MabThera/Rituxan, Clb=chlorambucil, CHOP=cyclophosphamide, doxorubicin, vincristine, prednisone, B=bendamustine Timelines shown (end of arrow) are expected data read-outs 40

41 Develop best-in-disease combinations in B-cell malignancies Treatment goal: Increase disease-free intervals; decrease toxicity & treatment burden R-chemo + Biologic modifier Strategy Replace with Gazyva Eliminate where possible Add a targeted agent (e.g. GDC-0199, ibrutinib, idelalisib, etc.) 41

42 Hematology franchise update Rick Fair, Franchise Head Roche Pharma, Global Product Strategy

43 Roche: Today a leader in hematology Top-15 hematology products globally Roche hematology sales lead MabThera/Rituxan Imatinib Sales in hematology indications Bortezomib Lenalidomide Dasatinib Nilotinib Bendamustine Dexamethasone Doxorubicin Cyclophosphamide Thalidomide Prednisone Topotecan Melphalan Fludarabine Source: Analysis based on IMS MIDAS, Q final database 43

44 More to come from broad & deep heme pipeline New combinations & molecules in more tumours Marketed products Clinical pipeline Hematological malignancies Other heme indications MM CLL anhl inhl Phase II 2013 Phase III Phase III Phase I Phase I Phase III Phase I Phase II Phase I AML 1995 Phase II Phase I Phase I Phase I Vesanoid MabThera/ Rituxan Erivedge Gazyva RG7601/ GDC-0199 (Bcl-2 inhibitor) ADC CD22 & ADC CD79b RG7388 (MDM2i) RG7598 (ADC) RG7356 (CD44 mab) AML=Acute Myeloid Leukemia, i/anhl=indolent/aggressive Non-Hodgkin Lymphoma, CLL=Chronic Lymphocytic Leukemia, MM=Multiple Myeloma. Other heme indications include myelodysplastic syndrome and small lymphocytic lymphoma 44

45 CD20 franchise: MabThera/Rituxan & Gazyva Backbones in B-cell hematology; NHL & CLL Sales by geography (CHF bn) US Europe Japan International MabThera/Rituxan: Standard of care Launched 1997 with subsequent label extensions in NHL and CLL Relapsed FL ( 97), DLBCL EU ( 01),1 st line FL EU ( 04), DLBCL US ( 06), 1 st line FL US ( 07), CLL ( 10), 1 st line FL maintenance ( 11) Successful geographical expansion to first Europe then international/emerging markets Subcutaneous (SC) approval expected in 2014 Gazyva: Next-generation CD20 backbone Launched US in CLL; proven superiority to MabThera/Rituxan Ongoing trials in core MabThera/Rituxan NHL indications 1 Sales at actual 2012 exchange rates global sales of CHF 6,707m included CHF 1,085m in Immunology(RA). Oncology sales split estimate is: ~50% in inhl, ~30% in anhl and ~20% in CLL. Source: Roche Annual Report 2012 and investor presentations 45

46 CD20 franchise: MabThera SC Expected EU regulatory approval in 2014 Reduces administration time from several hours down to 5-7 minutes No pharmacy dose preparation and no intravenous (IV) line needed Filed with EMA and other regulatory agencies Expect EU regulatory approval in

47 RG7601/GDC-0199: Potent Bcl-2 inhibitor Potential first-in-class & best-in-disease Re-introducing apoptosis GDC-0199 (ABT-199) is a highly selective, orally bioavailable, small molecule inhibitor of Bcl-2 Bcl-2 (B-cell lymphoma 2) is an attractive therapeutic target in CLL, and in DLBCL, FL, AML and MM given high expression levels in subsets of patients >100-fold improved functional selectivity for Bcl-2 over Bcl-x L in assays with tumor cell lines GDC-0199 Bcl-2 Bcl-w Collaboration with AbbVie Formed in 2007 with initial focus on two compounds; including ABT-263 (navitoclax) GDC-0199 (ABT-199) later chosen as an improved Bcl-2 inhibitor ABT-263 (navitoclax) Bcl-xL A-1 Mcl-1 Guardians of survival 47

48 GDC-0199 (ABT-199): Potent Bcl-2 inhibitor Key data highlights in multiple tumours CLL Presentation inhl Poster B-cell lymphoma w/ Gazyva Poster Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/ refractory (R/R) non-hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients Combination of the glycoengineered type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, GDC-0199, results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies Key insights from data Impressive response rates in R/R CLL ORR 84% (82% in 17p deletion patients; 89% in fludarabinerefractory patients) CR 23% Encouraging response rates in R/R NHL as single agent ORR 53% Pre-clinical synergy in combination with Gazyva R/R=Relapsed/Refractory, ORR=Overall Response Rate, CR=Complete Response 48

49 GDC-0199 (ABT-199): Potent Bcl-2 inhibitor Key data highlights in multiple tumours CLL Presentation inhl Poster B-cell lymphoma w/ Gazyva Poster Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/ refractory (R/R) non-hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients Combination of the glycoengineered type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, GDC-0199, results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies Potential for best-indisease efficacy Phase III starting in CLL 49

50 GDC-0199 (ABT-199): CLL development program Phase I study relapsed/refractory CLL 1 Relapsed/ refractory CLL GDC-0199 doseescalation 4 cohorts ( mg) Combination Gazyva+GDC cycles Single agent GDC-0199 to progression Establish the dose of Bcl-2 and safety of the combination (Q4 2013) Activity in expansion cohorts (2H 2014) Adjunct phase II study relapsed/refractory CLL with 17p deletion Relapsed/refractory CLL with 17 p deletion GDC mg Treatment to progression Primary end-point: Overall Response Rate FPI: Q Expect data: 2014/2015 Phase III study relapsed/refractory CLL (MURANO) Relapsed/refractory CLL MabThera/Rituxan + GDC-0199 X 6 cycles MabThera/Rituxan + bendamustine X 6 cycles GDC years Observation Primary end-point: PFS FPI: Q Expect data: 2016 Phase III study previously untreated CLL Previously untreated CLL Gazyva + GDC-0199 Gazyva + chlorambucil FPI: 2014 More details TBC 50 Additional studies NHL (phase I), multiple myeloma (phase I) & AML (phase I) 1 50 Other phase I studies ongoing, including as single agent, in combination with MabThera/Rituxan and MabThera/Rituxan & bendamustine

51 RG7593/RG7596: ADCs against CD22 & CD79b Phase I at ASH; head-to-head phase II on-going RG7593 ADC CD22 w/mabthera/ Rituxan Poster RG7596 ADC CD79b Poster Final results of a phase I study of the anti-cd22 antibody-drug conjugate (ADC) DCDT2980S with or without rituximab (RTX) in patients (Pts) with relapsed or refractory (R/R) B-cell non-hodgkin s lymphoma (NHL) Final results of a phase I study of the anti-cd79b antibody-drug conjugate DCDS4501A in relapsed or refractory (R/R) B-cell non-hodgkin lymphoma (NHL) Heavily pre-treated patients for whom very little, if any, comparative historical data exists CD22 study median of 3 prior regimens (range 1-11) and CD79b study median of 4 prior regimens (range 1-14) Phase I data show solid responses across multiple histologies, including i/anhl, MCL On-going head-to head phase II study ROMULUS NHL (R/R FL and 2/3 line DLBCL) N=120, PE PFS ADC CD22 + MabThera/Rituxan ADC CD79b + MabThera/Rituxan PD PD ADC CD79b + MabThera/Rituxan ADC CD22 + MabThera/Rituxan Expect data in 2014 and decision on next steps in clinical development ADC=Antibody Drug Conjugate 51

52 Hematology franchise: Transforming the treatment of hematologic cancers Extend leadership in hematology Pipeline molecules & combinations in other hematologic cancers Pipeline molecules in B-cell malignancies in combo with anti-cd20 MabThera/Rituxan Standard of care anti-cd20 mab in inhl, anhl, CLL Improve upon MabThera/Rituxan in CD20-positive hematologic cancers Gazyva: US trade name as approved by the FDA 52

53 Q&A

54 Appendix: Epidemiology MabThera/Rituxan & Gazyva Follicular Lymphoma (FL) (~inhl) 50, estimates for number of patients 45,000 40,000 35,000 30,000 25,000 20,000 15,000 10,000 5,000,0 22,800 24,700 Incident cases 39,400 21,400 18,000 Drug treated indolent 1st-line 19,700 11,800 7,900 Drug treated follicular 1st-line Top 5 EU US 11,300 5,600 5,700 Drug treated follicular relapsed Sources: Cancer Incidence in Five Continents, Vol. IX, Curado. M. P et al (2007), IARC Scientific Publications No. 160, Lyon, IARC; World Population Prospects; 2008 revision; medium variant; MabThera patient flow model; & patient case market research Q estimates only; US based on Census Bureau, SEER, Mattson Jack TA data, and Q Rituxan tracking; Genentech hematology epidemiology model 54

55 Appendix: Epidemiology MabThera/Rituxan & Gazyva Diffuse Large B-Cell Lymphoma (DLBCL) (~anhl) 80, estimates for number of patients 60,000 40,000 20,000 32,900 32,100 40,400 19,500 20,900 Top 5 EU US 0 Incident cases Drug treated DLBCL 1st-line Sources: Cancer Incidence in Five Continents, Vol. IX, Curado. M. P et al (2007), IARC Scientific Publications No. 160, Lyon, IARC; World Population Prospects; 2008 revision; medium variant; MabThera patient flow model; & patient case market research Q estimates only; US based on Census Bureau, SEER, Mattson Jack TA data, and Q Rituxan tracking; Genentech hematology epidemiology model 55

56 Appendix: Epidemiology MabThera/Rituxan, Gazyva & RG7601/GDC-0199 Chronic Lymphocytic Leukemia (CLL) 40, estimates for number of patients 20,000,0 Top 5 EU US 14,900 18,900 10,000 12,400 5,400 14,400 8,900 7,000 Incident cases CLL 1st-line CLL relapsed Drug treated Sources: Cancer Incidence in Five Continents, Vol. IX, Curado. M. P et al (2007), IARC Scientific Publications No. 160, Lyon, IARC; World Population Prospects; 2008 revision; medium variant; MabThera patient flow model; & patient case market research Q estimates only; US based on Census Bureau, SEER, Mattson Jack TA data, and Q Rituxan tracking; Genentech hematology epidemiology model 56

57 Doing now what patients need next

David Loew, LCL MabThera

David Loew, LCL MabThera MabThera The star continues to rise David Loew, LCL MabThera MabThera the star continues to raise Group sales (CHF bn) 4,5 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 2001 2002 2003 2004 2005 Outstanding clinical

More information

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies

More information

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,

More information

49th ASCO Annual Meeting, Chicago. Roche Analyst Event. Sunday, June 2, 2013

49th ASCO Annual Meeting, Chicago. Roche Analyst Event. Sunday, June 2, 2013 49th ASCO Annual Meeting, Chicago Roche Analyst Event Sunday, June 2, 2013 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such

More information

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Study Concepts Follicular Lymphomas Mantel Cell Lymphomas Waldenstroem s Disease Key Steps in Improving Treatment for Follicular

More information

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade

More information

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line

More information

New Targets and Treatments for Follicular Lymphoma. Disclosures

New Targets and Treatments for Follicular Lymphoma. Disclosures Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:

More information

Effective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm

Effective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Effective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Uses of Monoclonal Antibodies for the Treatment of Non-Hodgkin

More information

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN + IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start

More information

Frequency of NHL Subtypes in Adults

Frequency of NHL Subtypes in Adults Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults

More information

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

Bendamustine for the fourth-line treatment of multiple myeloma

Bendamustine for the fourth-line treatment of multiple myeloma LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard

More information

-Examination of key pipeline candidates with in-depth clinical and commercial profiles of Phase III candidates

-Examination of key pipeline candidates with in-depth clinical and commercial profiles of Phase III candidates Brochure More information from http://www.researchandmarkets.com/reports/1215469/ Pipeline Insight: Lymphomas, Multiple Myeloma & Myelodysplastic Syndromes - Optimization of clinical practice creates opportunities

More information

Roche Committed to innovation and profitable growth. Dr. Karl Mahler Head of Investor Relations. London, July 2011

Roche Committed to innovation and profitable growth. Dr. Karl Mahler Head of Investor Relations. London, July 2011 Roche Committed to innovation and profitable growth Dr. Karl Mahler Head of Investor Relations London, July 2011 2 This presentation contains certain forward-looking statements. These forward-looking statements

More information

Mantle Cell Lymphoma Understanding Your Treatment Options

Mantle Cell Lymphoma Understanding Your Treatment Options New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department

More information

6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic

6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic Follicular and Other Slow Growing Lymphomas Stephen Ansell, MD, PhD Mayo Clinic 1 Learning Objectives Start with an overview of Follicular and other slow growing lymphomas Discuss current and emerging

More information

CHRONIC LYMPHOCYTIC LEUKEMIA

CHRONIC LYMPHOCYTIC LEUKEMIA CHRONIC LYMPHOCYTIC LEUKEMIA Executive Summary Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the Western world, but is significantly less frequent in Asia. The median age of

More information

MorphoSys Proprietary Development Update

MorphoSys Proprietary Development Update September 8, 2015 MorphoSys Proprietary Development Update 1 Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Future strategies for myeloma: An overview of novel treatments In development

Future strategies for myeloma: An overview of novel treatments In development Future strategies for myeloma: An overview of novel treatments In development Dr. Matthew Streetly Guys and St. Thomas NHS Trust How far have we come? Melphalan and prednisolone VAD Autologous SCT Thalidomide

More information

rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited

rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited 06 June 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

Guidelines for the Management of Follicular Lymphoma

Guidelines for the Management of Follicular Lymphoma Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World

More information

Cure versus control: Which is the best strategy?

Cure versus control: Which is the best strategy? Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control

More information

Michael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto

Michael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto Evolution of Lymphoma Therapy: What can we expect for the rest of the millenium decade? Michael Crump MD Lymphoma Site Leader Princess Margaret Hospital University of Toronto disclaimers Served on advisory

More information

Histopathologic results

Histopathologic results Self evaluation 1 Clinical Case 55-year-old woman Bilateral enlargement of cervical, axillary and inguinal lymph nodes, largest diameter > 6 cm Hepatosplenomegaly. Enlargement of retroperitoneal, mesenteric

More information

Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma

Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma a report by Martin Dreyling Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma Head, Lymphoma Section, Department of Medicine III, University Hospital Großhadern, Ludwig Maximilians-University

More information

Update on Follicular Lymphoma. Brad Kahl, M.D.

Update on Follicular Lymphoma. Brad Kahl, M.D. Update on Follicular Lymphoma Brad Kahl, M.D. Follicular Lymphoma: 25% of NHL Cases Other subtypes (9%) T and NK cell (12%) Burkitt (2.5%) Diffuse large B cell (DLBCL) (30%) Mantle cell (6%) Follicular

More information

Rituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma

Rituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma Issue date: June 2011 Rituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma This guidance was developed using the the single technology appraisal process NICE technology

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

12. November 2013 Jan Endell. From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma

12. November 2013 Jan Endell. From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma 12. November 2013 Jan Endell From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma The MorphoSys Pipeline 21 Clinical Programs, 82 Total Program

More information

Dr. Stefan Frings, Global Head Medical Affairs Oncology

Dr. Stefan Frings, Global Head Medical Affairs Oncology Roche Innovation: Reinventing Healthcare Exane BNP Paribas 14 th Healthcare Conference May 10, 2012 Dr. Stefan Frings, Global Head Medical Affairs Oncology 1 This presentation contains certain forward-looking

More information

1. Introduction. 2. Clinical aspects

1. Introduction. 2. Clinical aspects 1. Introduction MabThera (rituximab) is a genetically engineered chimeric mouse/human monoclonal antibody which binds specifically to the transmembrane antigen, CD20. This antigen is located on pre-b-

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007

More information

Innovating antibodies, improving lives

Innovating antibodies, improving lives ANNUAL REPORT 2014 Innovating antibodies, improving lives Genmab A/S CVR No. 21 02 38 84 DIRECTORS REPORT TABLE OF CONTENTS PRODUCTS Table of Contents Directors Report page 1 Genmab At-A-Glance 1 Shareholder

More information

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype? Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in

More information

Novità dall EHA >> [ Leucemia linfatica cronica ]

Novità dall EHA >> [ Leucemia linfatica cronica ] Novità dall EHA >> [ Leucemia linfatica cronica ] Relatore: P. GHIA 27-28 ottobre 2008 Borgo S. Luigi Monteriggioni (Siena) Leucemia linfatica cronica - Copyright FSE 1 Number and type of abstracts 2 Number

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

Health Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc.

Health Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc. Health Disparities in Multiple Myeloma Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc. Multiple Myeloma Overview Multiple myeloma (MM) is a type of blood cancer that develops

More information

Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation May 2015

Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation May 2015 Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells Corporate Presentation May 2015 Forward-looking statements / safe harbor This presentation and the accompanying oral

More information

New Treatment Options for Breast Cancer

New Treatment Options for Breast Cancer New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of

More information

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,

More information

Henk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson

Henk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson DRTUMUMB, a CD38 Monoclonal ntibody Study in dvanced Multiple Myeloma an Open-Label, Dose Escalation Followed by Open-Label Extension in a Single-rm Phase I/II Study bstract #S576 Henk Lokhorst, Torben

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre

Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Background Non-Hodgkin s lymphoma (NHL) makes up approximately 85% of all lymphomas. They are a heterogeneous collection

More information

An overview of current CLL clinical trials in Europe

An overview of current CLL clinical trials in Europe An overview of current CLL clinical trials in Europe CENTER/GROUP TRIAL SITUATION CONTACT PERSONS OTHER REMARKS INFORMATION LAST Europewide Nordic-Dutch-Polish- Czech-Israeli Czech Republic Czech Leukemia

More information

Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR, MorphoSys AG

Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR, MorphoSys AG MorphoSys AG Pipeline Update - Conference Call Text September 8, 2015 The spoken word shall prevail. Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR, MorphoSys AG Safe Harbor Good afternoon

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT

More information

Pro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany

Pro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Several hematological malignancies can be cured

More information

Treatment of low-grade non-hodgkin lymphoma

Treatment of low-grade non-hodgkin lymphoma Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade

More information

CAR T cell therapy for lymphomas

CAR T cell therapy for lymphomas CAR T cell therapy for lymphomas Sattva S. Neelapu, MD Associate Professor and Deputy Chair ad interim Department of Lymphoma and Myeloma UT MD Anderson Cancer Center, Houston, TX CAR T cell therapy What

More information

In ELOQUENT-2, Empliciti was evaluated in patients who had received one to three prior

In ELOQUENT-2, Empliciti was evaluated in patients who had received one to three prior - First and only immunostimulatory antibody approved in the European Union for multiple myeloma - Accelerated assessment and approval based on long-term data from ELOQUENT-2, which evaluated Empliciti

More information

Innovating antibodies, improving lives

Innovating antibodies, improving lives Annual Report 2013 Innovating antibodies, improving lives Genmab A/S CVR No. 21 02 38 84 Table of Contents Directors Report Shareholder Letter 2 Impressive 2013 Achievements 4 Consolidated Key Figures

More information

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015 Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future

More information

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for

More information

UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD

UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. Petitioner, v. Biogen Idec, Inc.

More information

Chronic lymphocytic EBMT Slideleukemia. University of Heidelberg, Germany March 22, 2010. The European Group for Blood and Marrow Transplantation

Chronic lymphocytic EBMT Slideleukemia. University of Heidelberg, Germany March 22, 2010. The European Group for Blood and Marrow Transplantation Chronic lymphocytic EBMT Slideleukemia template Peter Barcelona Dreger Chairman, CLL 7 February subcommittee 2008 University of Heidelberg, Germany March 22, 2010 The European Group for Blood and Marrow

More information

Company Update. March 2011

Company Update. March 2011 Company Update March 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various

More information

[ NASDAQ: MEIP ] Bank of America Merrill Lynch Health Care Conference May 12-14, 2015

[ NASDAQ: MEIP ] Bank of America Merrill Lynch Health Care Conference May 12-14, 2015 [ NASDAQ: MEIP ] Bank of America Merrill Lynch Health Care Conference May 12-14, 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements.

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Cowen and Company 35 th Annual Healthcare Conference

Cowen and Company 35 th Annual Healthcare Conference Personalized Therapeutics The Power of Epigenetics Cowen and Company 35 th Annual Healthcare Conference March 2015 2013 Accomplishments Forward Looking Statements This presentation contains forward-looking

More information

Majority-stake investment in Acerta Pharma. 17December 2015

Majority-stake investment in Acerta Pharma. 17December 2015 Majority-stake investment in Acerta Pharma 17December 2015 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform

More information

DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY

DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY Torben Plesner, Henk Lokhorst, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson

More information

Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics

Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use

More information

Treatment results with Bortezomib in multiple myeloma

Treatment results with Bortezomib in multiple myeloma Treatment results with Bortezomib in multiple myeloma Prof. Dr. Orhan Sezer Hamburg University Medical Center Circulating proteasome levels are an independent prognostic factor in MM 1.0 Probability of

More information

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div. Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under

More information

Latest News in Blood Cancer Research

Latest News in Blood Cancer Research ASH 2009 REPORT Latest News in Blood Cancer Research Highlights from the 2009 Annual Meeting of the American Society of Hematology Editor David H. Henry, MD, FACP Pennsylvania Hospital Philadelphia, Pennsylvania

More information

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking Q1/2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties

More information

DNB Markets 5 th Annual Health Care Conference, 11 December 2014 CEO Luigi Costa

DNB Markets 5 th Annual Health Care Conference, 11 December 2014 CEO Luigi Costa DNB Markets 5 th Annual Health Care Conference, December 0 CEO Luigi Costa Nordic Nanovector ASA Kjelsåsveien 68 B, 088 Oslo, Norway - www.nordicnanovector.com Forward-looking statements This presentation

More information

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells

More information

Roche reports solid sales growth in the first quarter of 2016

Roche reports solid sales growth in the first quarter of 2016 Media Release Basel, 19 April 2016 Roche reports solid sales growth in the first quarter of 2016 Group sales up 4% 1 at constant exchange rates, 5% in Swiss francs Pharmaceuticals Division sales increase

More information

Multiple Myeloma (Event Driven)

Multiple Myeloma (Event Driven) Brochure More information from http://www.researchandmarkets.com/reports/2234830/ Multiple Myeloma (Event Driven) Description: The 2010 multiple myeloma (myeloma) market garnered impressive sales despite

More information

EU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com

EU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com EU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com Investor Relations: Stan Panasewicz Phone: +1 732-524-2524 Louise Mehrotra Phone:

More information

Outline of thesis and future perspectives.

Outline of thesis and future perspectives. Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy

More information

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Aggressive lymphomas. Michael Crump Princess Margaret Hospital Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies

More information

ICML CLL: Therapie des Rezidivs

ICML CLL: Therapie des Rezidivs ICML CLL: Therapie des Rezidivs Thomas Elter Universitätsklinikum Köln Deutsche CLL Studiengruppe 14.09.2013 Hamburg LUGANO: WAS GIBT ES ZUR CLL IN DER 2. LINIE? Publikationen zur CLL insgesamt: 55 Diagnostik

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

Practice of Interferon Therapy

Practice of Interferon Therapy Interferon Therapy Practice of Interferon Therapy Multiple myeloma and other related hematological malignancies JMAJ 47(1): 32 37, 2004 Akihisa KANAMARU* and Takashi ASHIDA** *Professor, **Lecturer, Department

More information

Rituximab in Non - Hodgkins Lymphoma. Fatima Bassa, Dept. of Haematology October 2008

Rituximab in Non - Hodgkins Lymphoma. Fatima Bassa, Dept. of Haematology October 2008 Rituximab in Non - Hodgkins Lymphoma Fatima Bassa, Dept. of Haematology October 2008 World Health Organization lymphoma classification (2001) Peripheral B-cell neoplasms: B-chronic lymphocytic leukemia/small

More information

NATIONAL CANCER DRUG FUND PRIORITISATION SCORES

NATIONAL CANCER DRUG FUND PRIORITISATION SCORES NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated

More information

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need?

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,

More information

Rituximab Maintenance for 2 Years in Patients with Untreated High Tumor Burden Follicular Lymphoma After Response to Immunochemotherapy

Rituximab Maintenance for 2 Years in Patients with Untreated High Tumor Burden Follicular Lymphoma After Response to Immunochemotherapy Rituximab Maintenance for 2 Years in Patients with Untreated High Tumor Burden Follicular Lymphoma After Response to Immunochemotherapy G. A. Salles, J. F. Seymour, P. Feugier, F. Offner, A. Lopez-Guillermo,

More information

DECISION AND SUMMARY OF RATIONALE

DECISION AND SUMMARY OF RATIONALE DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in

More information

The role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D.

The role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D. The role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D. Oncology Institute of Southern Switzerland (IOSI) Swiss Group for Clinical Cancer Research (SAKK) WHO grading of follicular lymphoma

More information

Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy

Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy Brochure More information from http://www.researchandmarkets.com/reports/1088137/ Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy Description: The drug therapy of acute

More information

The Clinical Trials Process an educated patient s guide

The Clinical Trials Process an educated patient s guide The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-

More information

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib

More information

SEPTEMBER 2015 MICHAEL OREDSSON,CEO

SEPTEMBER 2015 MICHAEL OREDSSON,CEO SEPTEMBER 2015 MICHAEL OREDSSON,CEO 2 INVESTMENT HIGHLIGHTS Combines the valuable n-coder library of 30 billion antibodies with the proprietary F.I.R.S.T technology to identify the right antibodies for

More information

C H R O N I C L Y M P H O C Y T I C L E U K E M I A

C H R O N I C L Y M P H O C Y T I C L E U K E M I A Review of Current Treatment Options and Evidence for the Use of Rituximab (Rituxan ) in the Treatment of C H R O N I C L Y M P H O C Y T I C L E U K E M I A Rituximab (Rituxan ) in the Treatment of Chronic

More information

Trials in Elderly Melanoma Patients (with a focus on immunotherapy)

Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP

More information

Follicular Lymphoma. Aruna K. Reddy, MD. Hematology& Oncology Peace Health Southwest Medical Center

Follicular Lymphoma. Aruna K. Reddy, MD. Hematology& Oncology Peace Health Southwest Medical Center Follicular Lymphoma Aruna K. Reddy, MD Hematology& Oncology Peace Health Southwest Medical Center Follicular Lymphoma Malignant neoplasm resulting from clonal proliferation of malignant B-cells Second

More information

Cancer, Autoimmune & Other Serious Diseases

Cancer, Autoimmune & Other Serious Diseases Focused on Therapy: Cancer, Autoimmune & Other Serious Diseases 2012 Wedbush PacGrow Life Sciences Conference Gerard Gorman, SVP Finance and CFO It s all about Life Good afternoon. I m Gerard Gorman. Thank

More information

Aeterna Zentaris. 11 th Annual Needham Healthcare Conference April 3, 2012. Committed to cure

Aeterna Zentaris. 11 th Annual Needham Healthcare Conference April 3, 2012. Committed to cure 11 th Annual Needham Healthcare Conference April 3, 2012 Forward-Looking Statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities

More information

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from

More information

Company Presentation June 2011 Biotest AG 0

Company Presentation June 2011 Biotest AG 0 Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and

More information

Genmab A/S Genmab Ltd. Genmab, Inc. Genmab MN, Inc.

Genmab A/S Genmab Ltd. Genmab, Inc. Genmab MN, Inc. 2009 Annual Report PRE-CLINICAL AND CLINICAL PRODUCT PIPELINE AS OF MARCH 2, 2010 Development Phase Product Disease Indications Pre-Clinical I I/II II III Ofatumumab 17 studies Partner: GSK Chronic lymphocytic

More information